Skip to main content Accessibility help
  • Print publication year: 2015
  • Online publication date: February 2015

26 - ADHD and smoking

Related content

Powered by UNSILO


1. EzzatiM, LopezAD. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003;362:847–52.
2. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults – United States, 2006. MMWR Morb Mortal Wkly Rep. 2007;56:1157–61.
3. GrantBF, HasinDS, ChouSP, StinsonFS, DawsonDA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2004;61:1107–15.
4. LasserK, BoydJW, WoolhandlerS, et al. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284:2606–10.
5. BreslauN. Psychiatric comorbidity of smoking and nicotine dependence. Behav Genet. 1995;25:95–101.
6. JohnU, MeyerC, RumpfHJ, HapkeU. Smoking, nicotine dependence and psychiatric comorbidity–a population-based study including smoking cessation after three years. Drug Alcohol Depend. 2004;76:287–95.
7. PomerleauOF, DowneyKK, StelsonFW, PomerleauCS. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse. 1995;7:373–8.
8. KollinsSH, McClernonFJ, FuemmelerBF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry. 2005;62:1142–7.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn., text rev. (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
10. RasmussenER, ToddRD, NeumanRJ, et al. Comparison of male adolescent-report of attention-deficit/hyperactivity disorder (ADHD) symptoms across two cultures using latent class and principal components analysis. J Child Psychol Psychiatry. 2002;43:797–805.
11. TercyakKP, LermanC, AudrainJ. Association of attention-deficit/hyperactivity disorder symptoms with levels of cigarette smoking in a community sample of adolescents. J Am Acad Child Adolesc Psychiatry. 2002;41:799–805.
12. ShiffmanS. Tobacco “chippers”–individual differences in tobacco dependence. Psychopharmacology (Berl). 1989;97:539–47.
13. DonnyEC, DierkerLC. The absence of DSM-IV nicotine dependence in moderate-to-heavy daily smokers. Drug Alcohol Depend. 2007;89:93–6.
14. CDC. Quitting smoking among adults–United States, 2001–2010. MMWR Morb Mortal Wkly Rep. 2011;60:1513–19.
15. CDC. Current cigarette smoking prevalence among working adults–United States, 2004–2010. MMWR Morb Mortal Wkly Rep. 2011;60:1305–9.
16. GilpinEA, ChoiWS, BerryC, PierceJP. How many adolescents start smoking each day in the United States?J Adolesc Health. 1999;25:248–55.
17. TuckerJS, EllicksonPL, KleinDJ. Predictors of the transition to regular smoking during adolescence and young adulthood. J Adolesc Health. 2003;32:314–24.
18. GritzER, CarrCR, MarcusAC. The tobacco withdrawal syndrome in unaided quitters. Br J Addict. 1991;86:57–69.
19. HughesJR, GulliverSB, FenwickJWet al. Smoking cessation among self-quitters. Health Psychol. 1992;11:331–4.
20. CroghanGA, SloanJA, CroghanIT, et al. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine Tob Res. 2003;5:181–7.
21. LermanC, KaufmannV, RukstalisM, et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann Intern Med. 2004;140:426–33.
22. NidesM, OnckenC, GonzalesD, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006;166:1561–8.
23. LambertNM, HartsoughCS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil. 1998;31:533–44.
24. MilbergerS, BiedermanJ, FaraoneSV, ChenL, JonesJ. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997;36:37–44.
25. MolinaBS, PelhamWE, Jr. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol. 2003;112:497–507.
26. BarkleyRA, FischerM, EdelbrockCS, SmallishL. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990;29:546–57.
27. BiedermanJ, WilensT, MickE, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1997;36:21–9.
28. BoyleMH, OffordDR. Psychiatric disorder and substance use in adolescence. Can J Psychiatry. 1991;36:699–705.
29. MilbergerS, BiedermanJ, FaraoneSV, WilensT, ChuMP. Associations between ADHD and psychoactive substance use disorders. Findings from a longitudinal study of high-risk siblings of ADHD children. Am J Addict. 1997;6:318–29.
30. AytaclarS, TarterRE, KirisciL, LuS. Association between hyperactivity and executive cognitive functioning in childhood and substance use in early adolescence. J Am Acad Child Adolesc Psychiatry. 1999;38:172–8.
31. BurkeJD, LoeberR, LaheyBB. Which aspects of ADHD are associated with tobacco use in early adolescence? J Child Psychol Psychiatry. 2001;42:493–502.
32. WhalenCK, JamnerLD, HenkerB, DelfinoRJ, LozanoJM. The ADHD spectrum and everyday life: experience sampling of adolescent moods, activities, smoking, and drinking. Child Dev. 2002;73:209–27.
33. PomerleauCS, DowneyKK, SnedecorSM, et al. Smoking patterns and abstinence effects in smokers with no ADHD, childhood ADHD, and adult ADHD symptomatology. Addict Behav. 2003;28:1149–57.
34. RohdeP, KahlerCW, LewinsohnPM, BrownRA. Psychiatric disorders, familial factors, and cigarette smoking: II. Associations with progression to daily smoking. Nicotine Tob Res. 2004;6:119–32.
35. FuemmelerBF, KollinsSH, McClernonFJ. Attention deficit hyperactivity disorder symptoms predict nicotine dependence and progression to regular smoking from adolescence to young adulthood. J Pediatr Psychol. 2007;32:1203–13.
36. McClernonFJ, KollinsSH, LutzAM, et al. Effects of smoking abstinence on adult smokers with and without attention deficit hyperactivity disorder: results of a preliminary study. Psychopharmacology (Berl). 2008;197:95–105.
37. HumfleetGL, ProchaskaJJ, MengisM, et al. Preliminary evidence of the association between the history of childhood attention-deficit/hyperactivity disorder and smoking treatment failure. Nicotine Tob Res. 2005;7:453–60.
38. XianH, ScherrerJF, MaddenPA, et al. The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. Nicotine Tob Res. 2003;5:245–54.
39. McClernonFJ, Van VoorheesEE, EnglishJ, et al. Smoking withdrawal symptoms are more severe among smokers with ADHD and independent of ADHD symptom change: results from a 12-day contingency-managed abstinence trial. Nicotine Tob Res. 2011;13:784–92.
40. FaraoneSV, PerlisRH, DoyleAE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1313–23.
41. LiMD, ChengR, MaJZ, SwanGE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction. 2003;98:23–31.
42. LiMD, MaJZ, BeutenJ. Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clin Genet. 2004;66:382–92.
43. MaherBS, MarazitaML, FerrellRE, VanyukovMM. Dopamine system genes and attention deficit hyperactivity disorder: a meta-analysis. Psychiatr Genet. 2002;12:207–15.
44. MunafoM, ClarkT, JohnstoneE, MurphyM, WaltonR. The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res. 2004;6:583–97.
45. ToddRD, HuangH, SmalleySL, et al. Collaborative analysis of DRD4 and DAT genotypes in population-defined ADHD subtypes. J Child Psychol Psychiatry. 2005;46:1067–73.
46. McGoughJJ.Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry. 2005;57:1367–73.
47. HamarmanS, FossellaJ, UlgerC, BrimacombeM, DermodyJ. Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study. J Child Adolesc Psychopharmacol. 2004;14:564–74.
48. JooberR, GrizenkoN, SenguptaS, et al. Dopamine transporter 3′-UTR VNTR genotype and ADHD: a pharmaco-behavioural genetic study with methylphenidate. Neuropsychopharmacology. 2007;32:1370–6.
49. SteinMA, WaldmanID, SarampoteCS, et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology. 2005;30:1374–82.
50. McGoughJ, McCrackenJ, SwansonJ, et al. Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1314–22.
51. AlbayrakO, FriedelS, SchimmelmannBG, HinneyA, HebebrandJ. Genetic aspects in attention-deficit/hyperactivity disorder. J Neural Transm. 2008;115:305–15.
52. Arcos-BurgosM, CastellanosFX, PinedaD, et al. Attention-deficit/hyperactivity disorder in a population isolate: linkage to loci at 4q13.2, 5q33.3, 11q22, and 17p11. Am J Hum Genet. 2004;75:998–1014.
53. BakkerSC, van der MeulenEM, BuitelaarJK, et al. A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder: suggestive evidence for linkage on chromosomes 7p and 15q. Am J Hum Genet. 2003;72:1251–60.
54. OgdieMN, BakkerSC, FisherSE, et al. Pooled genome-wide linkage data on 424 ADHD ASPs suggests genetic heterogeneity and a common risk locus at 5p13. Mol Psychiatry. 2006;11:5–8.
55. HebebrandJ, DempfleA, SaarK, et al. A genome-wide scan for attention-deficit/hyperactivity disorder in 155 German sib-pairs. Mol Psychiatry. 2006;11:196–205.
56. ManolioTA, RodriguezLL, BrooksL, et al. New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nat Genet. 2007;39:1045–51.
57. GerraG, GarofanoL, ZaimovicA, et al. Association of the serotonin transporter promoter polymorphism with smoking behavior among adolescents. Am J Med Genet B Neuropsychiatr Genet. 2005;135:73–8.
58. HutchisonKE, LaChanceH, NiauraR, BryanA, SmolenA. The DRD4 VNTR polymorphism influences reactivity to smoking cues. J Abnorm Psychol. 2002;111:134–43.
59. IshikawaH, OhtsukiT, IshiguroH, et al. Association between serotonin transporter gene polymorphism and smoking among Japanese males. Cancer Epidemiol Biomarkers Prev. 1999;8:831–3.
60. LererE, KanyasK, KarniO, EbsteinRP, LererB. Why do young women smoke? II. Role of traumatic life experience, psychological characteristics and serotonergic genes. Mol Psychiatry. 2006;11:771–81.
61. LermanC, CaporasoN, MainD, et al. Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene. Health Psychology. 1998;17:56–62.
62. LucianoM, ZhuG, KirkKM, et al. Effects of dopamine receptor D4 variation on alcohol and tobacco use and on novelty seeking: multivariate linkage and association analysis. Am J Med Genet B Neuropsychiatr Genet. 2004;124:113–23.
63. SkowronekMH, LauchtM, HohmE, BeckerK, SchmidtMH. Interaction between the dopamine D4 receptor and the serotonin transporter promoter polymorphisms in alcohol and tobacco use among 15-year-olds. Neurogenetics. 2006;7:239–46.
64. TapperAR, McKinneySL, NashmiR, et al. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science. 2004;306:1029–32.
65. TimberlakeDS, HaberstickBC, LessemJM, et al. An association between the DAT1 polymorphism and smoking behavior in young adults from the National Longitudinal Study of Adolescent Health. Health Psychol. 2006;25:190–7.
66. SullivanPF, NealeMC, SilvermanMA, et al. An association study of DRD5 with smoking initiation and progression to nicotine dependence. Am J Med Genet. 2001;105:259–65.
67. McClernonFJ, HutchisonKE, RoseJE, KozinkRV. DRD4 VNTR polymorphism is associated with transient fMRI-BOLD responses to smoking cues. Psychopharmacology (Berl). 2007;194:433–41.
68. GreenbaumL, KanyasK, KarniO, et al. Why do young women smoke? I. Direct and interactive effects of environment, psychological characteristics and nicotinic cholinergic receptor genes. Mol Psychiatry. 2006;11:312–22, 223.
69. HutchisonKE, AllenDL, FilbeyFM, et al. CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch Gen Psychiatry. 2007;64:1078–86.
70. LiMD, BeutenJ, MaJZ, et al. Ethnic- and gender-specific association of the nicotinic acetylcholine receptor alpha4 subunit gene (CHRNA4) with nicotine dependence. Hum Mol Genet. 2005;14:1211–19.
71. EhringerMA, CleggHV, CollinsAC, et al. Association of the neuronal nicotinic receptor beta2 subunit gene (CHRNB2) with subjective responses to alcohol and nicotine. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:596–604.
72. LiMD. Identifying susceptibility loci for nicotine dependence: 2008 update based on recent genome-wide linkage analyses. Hum Genet. 2008;123:119–31.
73. LermanCE, SchnollRA, MunafoMR. Genetics and smoking cessation improving outcomes in smokers at risk. Am J Prev Med. 2007;33:S398–405.
74. YudkinP, MunafoM, HeyK, et al. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ. 2004;328:989–90.
75. DavidSP, BrownRA, PapandonatosGD, et al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res. 2007;9:821–33.
76. McClernonFJ, FuemmelerBF, KollinsSH, KailME, Ashley-KochAE. Interactions between genotype and retrospective ADHD symptoms predict lifetime smoking risk in a sample of young adults. Nicotine Tob Res. 2008;10:117–27.
77. NeumanRJ, LobosE, ReichW, et al. Prenatal smoking exposure and dopaminergic genotypes interact to cause a severe ADHD subtype. Biol Psychiatry. 2007;61:1320–8.
78. ToddRD, NeumanRJ. Gene-environment interactions in the development of combined type ADHD: evidence for a synapse-based model. Am J Med Genet B Neuropsychiatr Genet. 2007;144:971–5.
79. KentL, MiddleF, HawiZ, et al. Nicotinic acetylcholine receptor alpha4 subunit gene polymorphism and attention deficit hyperactivity disorder. Psychiatr Genet. 2001;11:37–40.
80. ToddRD, LobosEA, SunLW, NeumanRJ. Mutational analysis of the nicotinic acetylcholine receptor alpha 4 subunit gene in attention deficit/hyperactivity disorder: evidence for association of an intronic polymorphism with attention problems. Mol Psychiatry. 2003;8:103–8.
81. BrookesK, XuX, ChenW, et al. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry. 2006;11:934–53.
82. GuanL, WangB, ChenY, et al. A high-density single-nucleotide polymorphism screen of 23 candidate genes in attention deficit hyperactivity disorder: suggesting multiple susceptibility genes among Chinese Han population. Mol Psychiatry. 2009;14:546–54.
83. LeeJ, LaurinN, CrosbieJ, et al. Association study of the nicotinic acetylcholine receptor alpha4 subunit gene, CHRNA4, in attention-deficit hyperactivity disorder. Genes Brain Behav. 2008;7:53–60.
84. KentL, GreenE, HolmesJ, et al. No association between CHRNA7 microsatellite markers and attention-deficit hyperactivity disorder. Am J Med Genet. 2001;105:686–9.
85. VoineskosS, De LucaV, MensahA, et al. Association of alpha4beta2 nicotinic receptor and heavy smoking in schizophrenia. J Psychiatry Neurosci. 2007;32:412–16.
86. GraceAA.Psychostimulant actions on dopamine and limbic system function: relevance to the pathophysiology and treatment of ADHD. In: SolantoM, ArnstenA, CastellanosF, eds. Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. London: Oxford University Press. 2001; 134–57.
87. SolantoMV.Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res. 1998;94:127–52.
88. CheonKA, RyuYH, KimYK, et al. Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder. Eur J Nucl Med Mol Imaging. 2003;30:306–11.
89. DoughertyDD, BonabAA, SpencerTJ, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet. 1999;354:2132–3.
90. DreselS, KrauseJ, KrauseKH, et al. Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med. 2000;27:1518–24.
91. KrauseKH, DreselSH, KrauseJ, KungHF, TatschK. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett. 2000;285:107–10.
92. KrauseKH, DreselSH, KrauseJ, et al. Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2002;5:111–13.
93. KrauseKH, DreselSH, KrauseJ, la FougereC, AckenheilM. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci Biobehav Rev. 2003;27:605–13.
94. LarischR, SitteW, AntkeC, et al. Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder. Nucl Med Commun. 2006;27:267–70.
95. SpencerTJ, BiedermanJ, MadrasBK, et al. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry. 2005;57:1293–300.
96. VolkowND, WangGJ, NewcornJ, et al. Brain dopamine transporter levels in treatment and drug naive adults with ADHD. Neuroimage. 2007;34:1182–90.
97. VolkowND, WangGJ, KollinsSH, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. 2009;302:1084–91.
98. BrodyAL, OlmsteadRE, LondonED, et al. Smoking-induced ventral striatum dopamine release. Am J Psychiatry. 2004;161:1211–18.
99. CorrigallWA, CoenKM, AdamsonKL. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res. 1994;653:278–84.
100. GlassK, FloryK. Why does ADHD confer risk for cigarette smoking? A review of psychosocial mechanisms. Clin Child Fam Psychol Rev. 2010;13:291–313.
101. HahnB, StolermanIP. Nicotine-induced attentional enhancement in rats: effects of chronic exposure to nicotine. Neuropsychopharmacology. 2002;27:712–22.
102. KoelegaHS. Stimulant drugs and vigilance performance: a review. Psychopharmacology (Berl). 1993;111:1–16.
103. RezvaniAH, LevinED. Cognitive effects of nicotine. Biol Psychiatry. 2001;49:258–67.
104. LevinED, ConnersCK, SilvaD, et al. Transdermal nicotine effects on attention. Psychopharmacology (Berl). 1998;140:135–41.
105. WarburtonDM, MancusoG. Evaluation of the information processing and mood effects of a transdermal nicotine patch. Psychopharmacology (Berl). 1998;135:305–10.
106. SaccoKA, TermineA, SeyalA, et al. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry. 2005;62:649–69.
107. LevinED, ConnersCK, SparrowE, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 1996;123:55–63.
108. BarkleyRA.Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull. 1997;121:65–94.
109. McClernonFJ, HiottFB, WestmanEC, RoseJE, LevinED. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2006;189:125–33.
110. LevinED, ConnersCK, SilvaD, CanuW, MarchJ. Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol. 2001;9:83–90.
111. PotterAS, NewhousePA. Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 2004;176:182–94.
112. PotterAS, NewhousePA. Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder. Pharmacol Biochem Behav. 2008;88:407–17.
113. WilensTE, BiedermanJ, SpencerTJ, et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1999;156:1931–7.
114. WilensTE, VerlindenMH, AdlerLA, WozniakPJ, WestSA. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry. 2006;59:1065–70.
115. FaraoneSV, BuitelaarJ. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19:353–64.
116. FaraoneSV, GlattSJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71:754–63.
117. MickE, BiedermanJ, FaraoneSV. Comment on Lambert and Hartsough (1998). J Learn Disabil. 2000;33:314.
118. BarkleyRA, FischerM, SmallishL, FletcherK. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics. 2003;111:97–109.
119. FaraoneSV, BiedermanJ, WilensTE, AdamsonJ. A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults. Psychol Med. 2007;37:1743–52.
120. WilensTE, VitulanoM, UpadhyayaH, et al. Concordance between cigarette smoking and the modified Fagerstrom Tolerance Questionnaire in controlled studies of ADHD. Am J Addict. 2008;17:491–6.
121. WhalenCK, JamnerLD, HenkerB, GehrickeJG, KingPS. Is there a link between adolescent cigarette smoking and pharmacotherapy for ADHD?Psychol Addict Behav. 2003;17:332–5.
122. SigmonSC, TideyJW, BadgerGJ, HigginsST. Acute effects of D-amphetamine on progressive-ratio performance maintained by cigarette smoking and money. Psychopharmacology (Berl). 2003;167:393–402.
123. TideyJW, O’NeillSC, HigginsST. d-amphetamine increases choice of cigarette smoking over monetary reinforcement. Psychopharmacology (Berl). 2000;153:85–92.
124. RushCR, HigginsST, VansickelAR, StoopsWW, LileJA, GlaserPE. et al. Methylphenidate increases cigarette smoking. Psychopharmacology (Berl). 2005;181:781–9.
125. StoopsWW, PooleMM, VansickelAR, et al. Methylphenidate increases choice of cigarettes over money. Nicotine Tob Res. 2011;13:29–33.
126. VansickelAR, StoopsWW, GlaserPE, PooleMM, RushCR. Methylphenidate increases cigarette smoking in participants with ADHD. Psychopharmacology (Berl). 2011;218:381–90.
127. GehrickeJG, HongN, WigalTL, ChanV, DoanA. ADHD medication reduces cotinine levels and withdrawal in smokers with ADHD. Pharmacol Biochem Behav. 2011;98:485–91.
128. WinhusenTM, SomozaEC, BrighamGS, et al. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010;71:1680–8.
129. BagwellCL, MolinaBS, PelhamWE, Jr., HozaB. Attention-deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence. J Am Acad Child Adolesc Psychiatry. 2001;40:1285–92.
130. DoranN, SpringB, McChargueD, PergadiaM, RichmondM. Impulsivity and smoking relapse. Nicotine Tob Res. 2004;6:641–7.
131. DowneyKK, PomerleauCS, PomerleauOF. Personality differences related to smoking and adult attention deficit hyperactivity disorder. J Subst Abuse. 1996;8:129–35.
132. DuBoisDL, SilverthornN. Do deviant peer associations mediate the contributions of self-esteem to problem behavior during early adolescence? A 2-year longitudinal study. J Clin Child Adolesc Psychol. 2004;33:382–8.
133. LejuezCW, AklinWM, JonesHA, et al. The Balloon Analogue Risk Task (BART) differentiates smokers and nonsmokers. Exp Clin Psychopharmacol. 2003;11:26–33.
134. MitchellSH. Measures of impulsivity in cigarette smokers and non-smokers. Psychopharmacology (Berl). 1999;146:455–64.
135. PomerleauCS.Co-factors for smoking and evolutionary psychobiology. Addiction. 1997;92:397–408.
136. ReynoldsB, RichardsJB, HornK, KarrakerK. Delay discounting and probability discounting as related to cigarette smoking status in adults. Behav Processes. 2004;65:35–42.
137. Finzi-DottanR, ManorI, TyanoS. ADHD, temperament, and parental style as predictors of the child’s attachment patterns. Child Psychiatry Hum Dev. 2006;37:103–14.
138. HarakehZ, ScholteRH, VermulstAA, de VriesH, EngelsRC. Parental factors and adolescents’ smoking behavior: an extension of the theory of planned behavior. Prev Med. 2004;39:951–61.
139. LauchtM, HohmE, EsserG, SchmidtMH, BeckerK. Association between ADHD and smoking in adolescence: shared genetic, environmental and psychopathological factors. J Neural Transm. 2007;114:1097–104.
140. MarshalMP, MolinaBS. Antisocial behaviors moderate the deviant peer pathway to substance use in children with ADHD. J Clin Child Adolesc Psychol. 2006;35:216–26.
141. Simons-MortonB, HaynieDL, CrumpAD, EitelSP, SaylorKE. Peer and parent influences on smoking and drinking among early adolescents. Health Educ Behav. 2001;28:95–107.
142. DobbinsM, DecorbyK, ManskeS, GoldblattE. Effective practices for school-based tobacco use prevention. Prev Med. 2008;46:289–97.
143. ThomasR, PereraR. School-based programmes for preventing smoking. Cochrane Database Syst Rev. 2006;3:CD001293.
144. HozaB. Peer functioning in children with ADHD. J Pediatr Psychol. 2007;32:655–63.
145. MolinaBS, MarshalMP, PelhamWE, Jr., WirthRJ. Coping skills and parent support mediate the association between childhood attention-deficit/hyperactivity disorder and adolescent cigarette use. J Pediatr Psychol. 2005;30:345–57.
146. MonuteauxMC, SpencerTJ, FaraoneSV, WilsonAM, BiedermanJ. A randomized, placebo-controlled clinical trial of bupropion for the prevention of smoking in children and adolescents with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2007;68:1094–101.
147. CoveyLS, HuMC, WeissmanJ, et al. Divergence by ADHD subtype in smoking cessation response to OROS-methylphenidate. Nicotine Tob Res. 2011;13:1003–8.
148. DwoskinLP, RauhutAS, King-PospisilKA, BardoMT. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev. 2006;12:178–207.
149. WilensTE, HaightBR, HorriganJP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry. 2005;57:793–801.
150. UpadhyayaHP, BradyKT, WangW. Bupropion SR in adolescents with comorbid ADHD and nicotine dependence: a pilot study. J Am Acad Child Adolesc Psychiatry. 2004;43:199–205.
151. SafrenSA.Cognitive-behavioral approaches to ADHD treatment in adulthood. J Clin Psychiatry. 2006;67(Suppl 8):46–50.